Literature DB >> 10495460

Randomization-based methods for correcting for treatment changes: examples from the Concorde trial.

I R White1, A G Babiker, S Walker, J H Darbyshire.   

Abstract

We develop analysis methods for clinical trials with time-to-event outcomes which correct for treatment changes during follow-up, yet are based on comparisons of randomized groups and not of selected groups. A causal model relating observed event times to event times that would have been observed under other treatment scenarios is fitted using the semi-parametric approach of Robins and Tsiatis (avoiding assumptions about the relationship between treatment changes and prognosis). The methods are applied to the Concorde trial of immediate versus deferred zidovudine, to investigate how the results would have differed if no participant randomized to deferred zidovudine had started treatment before reaching ARC or AIDS. We consider issues relating to model choice, non-constant treatment effects and censoring. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495460     DOI: 10.1002/(sici)1097-0258(19991015)18:19<2617::aid-sim187>3.0.co;2-e

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  Causal proportional hazards models and time-constant exposure in randomized clinical trials.

Authors:  T Loeys; E Goetghebeur; A Vandebosch
Journal:  Lifetime Data Anal       Date:  2005-12       Impact factor: 1.588

2.  Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.

Authors:  Nicholas R Latimer; Keith R Abrams; Mayur M Amonkar; Ceilidh Stapelkamp; R Suzanne Swann
Journal:  Oncologist       Date:  2015-06-03

3.  rpsftm: An R Package for Rank Preserving Structural Failure Time Models.

Authors:  Annabel Allison; Ian R White; Simon Bond
Journal:  R J       Date:  2017-12-04       Impact factor: 3.984

4.  Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

Authors:  James P Morden; Paul C Lambert; Nicholas Latimer; Keith R Abrams; Allan J Wailoo
Journal:  BMC Med Res Methodol       Date:  2011-01-11       Impact factor: 4.615

5.  Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study.

Authors:  Qingxia Chen; Fan Zhang; Ming-Hui Chen; Xiuyu Julie Cong
Journal:  Lifetime Data Anal       Date:  2020-03-03       Impact factor: 1.429

6.  Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.

Authors:  Nicholas R Latimer; Helen Bell; Keith R Abrams; Mayur M Amonkar; Michelle Casey
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452

7.  A causal model for longitudinal randomised trials with time-dependent non-compliance.

Authors:  Taeko Becque; Ian R White; Mark Haggard
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

8.  Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Konstantina Skaltsa; Cristina Ivanescu; Shevani Naidoo; Stefan Holmstrom; Nicholas R Latimer
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

9.  Randomised controlled trials and clinical maternity care: moving on from intention-to-treat and other simplistic analyses of efficacy.

Authors:  A W Welsh
Journal:  BMC Pregnancy Childbirth       Date:  2013-01-17       Impact factor: 3.007

10.  Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.

Authors:  Jack Bowden; Shaun Seaman; Xin Huang; Ian R White
Journal:  Stat Med       Date:  2015-11-17       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.